Pharmacological characterisation of the β-adrenoceptor expressed by human lung mast cells

Lee K. Chong, Russell Chess-Williams, Peter T. Peachell

Research output: Contribution to journalArticleResearchpeer-review

28 Citations (Scopus)

Abstract

The nonselective β-adrenoceptor agonist, isoprenaline (pD2; 8.8±0.2), and selective β2-adrenoceptor agonists, clenbuterol (9.2±0.4) and salbutamol (7.1±0.1), inhibited the immunoglobulin E-mediated release of histamine from human lung mast cells in a concentration-dependent manner. The β2-adrenoceptor-selective antagonist, ICI118551 (erythro-(±)-1-(7-methylindan-4-yloyl)-3-isopropylaminobutan-2-ol HCl), antagonised the isoprenaline inhibition of histamine release from human lung mast cells with high affinity (apparent pKB; 9.5±0.2), whereas high concentrations of the β1-adrenoceptor-selective antagonist, CGP20712A (2-hydroxy-5-(2-(hydroxy-3-(4((1-methyl-4-trifluoromethyl)-1-H- imidazol-2-yl)-phenoxy)-propyl)-aminoethoxyl)-benzamide), were required to reverse the isoprenaline inhibition (apparent pKB; 6.5±0.3). Radioligand binding studies using [125I]-iodocyanopindolol ([125I]CYP) were performed on membranes derived from purified mast cells (>90% purity). Binding of [125I]CYP to mast cell membranes was displaced from a single binding site with a high affinity for ICI118551 (pKi; 8.9±0.1) and low affinity for CGP20712A (pKi; 6.0±0.03), indicative of a homogeneous population of β2-adrenoceptors. In contrast, in human lung membranes, these antagonists displaced [125I]CYP from two sites indicative of a heterogeneous population of β1-adrenoceptors (20%) and β2-adrenoceptors (80%). These data indicate that the β-adrenoceptor expressed by human lung mast cells and mediating inhibition of mediator release from these cells is the β2-adrenoceptor.

Original languageEnglish
Pages (from-to)1-7
Number of pages7
JournalEuropean Journal of Pharmacology
Volume437
Issue number1-2
DOIs
Publication statusPublished - 15 Feb 2002
Externally publishedYes

Fingerprint

Mast Cells
Adrenergic Receptors
Pharmacology
Lung
Isoproterenol
Histamine Release
Iodocyanopindolol
Clenbuterol
Membranes
Albuterol
Immunoglobulin E
Population
Binding Sites
Cell Membrane

Cite this

@article{b98e3d9a7cfd4f48a299cec39bf7fabf,
title = "Pharmacological characterisation of the β-adrenoceptor expressed by human lung mast cells",
abstract = "The nonselective β-adrenoceptor agonist, isoprenaline (pD2; 8.8±0.2), and selective β2-adrenoceptor agonists, clenbuterol (9.2±0.4) and salbutamol (7.1±0.1), inhibited the immunoglobulin E-mediated release of histamine from human lung mast cells in a concentration-dependent manner. The β2-adrenoceptor-selective antagonist, ICI118551 (erythro-(±)-1-(7-methylindan-4-yloyl)-3-isopropylaminobutan-2-ol HCl), antagonised the isoprenaline inhibition of histamine release from human lung mast cells with high affinity (apparent pKB; 9.5±0.2), whereas high concentrations of the β1-adrenoceptor-selective antagonist, CGP20712A (2-hydroxy-5-(2-(hydroxy-3-(4((1-methyl-4-trifluoromethyl)-1-H- imidazol-2-yl)-phenoxy)-propyl)-aminoethoxyl)-benzamide), were required to reverse the isoprenaline inhibition (apparent pKB; 6.5±0.3). Radioligand binding studies using [125I]-iodocyanopindolol ([125I]CYP) were performed on membranes derived from purified mast cells (>90{\%} purity). Binding of [125I]CYP to mast cell membranes was displaced from a single binding site with a high affinity for ICI118551 (pKi; 8.9±0.1) and low affinity for CGP20712A (pKi; 6.0±0.03), indicative of a homogeneous population of β2-adrenoceptors. In contrast, in human lung membranes, these antagonists displaced [125I]CYP from two sites indicative of a heterogeneous population of β1-adrenoceptors (20{\%}) and β2-adrenoceptors (80{\%}). These data indicate that the β-adrenoceptor expressed by human lung mast cells and mediating inhibition of mediator release from these cells is the β2-adrenoceptor.",
author = "Chong, {Lee K.} and Russell Chess-Williams and Peachell, {Peter T.}",
year = "2002",
month = "2",
day = "15",
doi = "10.1016/S0014-2999(02)01263-3",
language = "English",
volume = "437",
pages = "1--7",
journal = "Acta physiologica et pharmacologica Neerlandica",
issn = "0014-2999",
publisher = "Elsevier",
number = "1-2",

}

Pharmacological characterisation of the β-adrenoceptor expressed by human lung mast cells. / Chong, Lee K.; Chess-Williams, Russell; Peachell, Peter T.

In: European Journal of Pharmacology, Vol. 437, No. 1-2, 15.02.2002, p. 1-7.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Pharmacological characterisation of the β-adrenoceptor expressed by human lung mast cells

AU - Chong, Lee K.

AU - Chess-Williams, Russell

AU - Peachell, Peter T.

PY - 2002/2/15

Y1 - 2002/2/15

N2 - The nonselective β-adrenoceptor agonist, isoprenaline (pD2; 8.8±0.2), and selective β2-adrenoceptor agonists, clenbuterol (9.2±0.4) and salbutamol (7.1±0.1), inhibited the immunoglobulin E-mediated release of histamine from human lung mast cells in a concentration-dependent manner. The β2-adrenoceptor-selective antagonist, ICI118551 (erythro-(±)-1-(7-methylindan-4-yloyl)-3-isopropylaminobutan-2-ol HCl), antagonised the isoprenaline inhibition of histamine release from human lung mast cells with high affinity (apparent pKB; 9.5±0.2), whereas high concentrations of the β1-adrenoceptor-selective antagonist, CGP20712A (2-hydroxy-5-(2-(hydroxy-3-(4((1-methyl-4-trifluoromethyl)-1-H- imidazol-2-yl)-phenoxy)-propyl)-aminoethoxyl)-benzamide), were required to reverse the isoprenaline inhibition (apparent pKB; 6.5±0.3). Radioligand binding studies using [125I]-iodocyanopindolol ([125I]CYP) were performed on membranes derived from purified mast cells (>90% purity). Binding of [125I]CYP to mast cell membranes was displaced from a single binding site with a high affinity for ICI118551 (pKi; 8.9±0.1) and low affinity for CGP20712A (pKi; 6.0±0.03), indicative of a homogeneous population of β2-adrenoceptors. In contrast, in human lung membranes, these antagonists displaced [125I]CYP from two sites indicative of a heterogeneous population of β1-adrenoceptors (20%) and β2-adrenoceptors (80%). These data indicate that the β-adrenoceptor expressed by human lung mast cells and mediating inhibition of mediator release from these cells is the β2-adrenoceptor.

AB - The nonselective β-adrenoceptor agonist, isoprenaline (pD2; 8.8±0.2), and selective β2-adrenoceptor agonists, clenbuterol (9.2±0.4) and salbutamol (7.1±0.1), inhibited the immunoglobulin E-mediated release of histamine from human lung mast cells in a concentration-dependent manner. The β2-adrenoceptor-selective antagonist, ICI118551 (erythro-(±)-1-(7-methylindan-4-yloyl)-3-isopropylaminobutan-2-ol HCl), antagonised the isoprenaline inhibition of histamine release from human lung mast cells with high affinity (apparent pKB; 9.5±0.2), whereas high concentrations of the β1-adrenoceptor-selective antagonist, CGP20712A (2-hydroxy-5-(2-(hydroxy-3-(4((1-methyl-4-trifluoromethyl)-1-H- imidazol-2-yl)-phenoxy)-propyl)-aminoethoxyl)-benzamide), were required to reverse the isoprenaline inhibition (apparent pKB; 6.5±0.3). Radioligand binding studies using [125I]-iodocyanopindolol ([125I]CYP) were performed on membranes derived from purified mast cells (>90% purity). Binding of [125I]CYP to mast cell membranes was displaced from a single binding site with a high affinity for ICI118551 (pKi; 8.9±0.1) and low affinity for CGP20712A (pKi; 6.0±0.03), indicative of a homogeneous population of β2-adrenoceptors. In contrast, in human lung membranes, these antagonists displaced [125I]CYP from two sites indicative of a heterogeneous population of β1-adrenoceptors (20%) and β2-adrenoceptors (80%). These data indicate that the β-adrenoceptor expressed by human lung mast cells and mediating inhibition of mediator release from these cells is the β2-adrenoceptor.

UR - http://www.scopus.com/inward/record.url?scp=0037084297&partnerID=8YFLogxK

U2 - 10.1016/S0014-2999(02)01263-3

DO - 10.1016/S0014-2999(02)01263-3

M3 - Article

VL - 437

SP - 1

EP - 7

JO - Acta physiologica et pharmacologica Neerlandica

JF - Acta physiologica et pharmacologica Neerlandica

SN - 0014-2999

IS - 1-2

ER -